
IBM Stock: Stable Dividend or Stagnant Investment?
The AI race has heated up significantly but returns on…
Trailing 12 Months | Fiscal Quarters | |||||
---|---|---|---|---|---|---|
Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
Income Statement | ||||||
Revenue | -- | -- | -- | -- | -- | |
Gross Profit | -- | -- | -- | -- | -- | |
Operating Income | -$372.3M | -$177.3M | -$159.1M | -$48.2M | -$19.8M | |
EBITDA | -$365.6M | -$171.2M | -$154.7M | -$46.7M | -$18.9M | |
Diluted EPS | -$6.76 | -$1.92 | -$2.04 | -$0.52 | -$0.21 |
Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
---|---|---|---|---|---|---|
Balance Sheet | ||||||
Current Assets | $424.8M | $531.5M | $339.2M | $218.3M | $97.2M | |
Total Assets | $440.5M | $621.1M | $418.6M | $283.5M | $124.4M | |
Current Liabilities | $18.9M | $40.6M | $27.6M | $23.5M | $16M | |
Total Liabilities | $26.7M | $96.5M | $74.4M | $62.5M | $51.7M | |
Total Equity | $413.8M | $524.6M | $344.2M | $221M | $72.7M | |
Total Debt | -- | -- | -- | -- | -- |
Trailing 12 Months | Fiscal Quarters | |||||
---|---|---|---|---|---|---|
Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
Cash Flow Statement | ||||||
Cash Flow Operations | -$298.6M | -$139M | -$105.4M | -$29.5M | -$31.7M | |
Cash From Investing | $86.1M | $1.5M | $45.2M | $31.5M | $15.6M | |
Cash From Financing | $142.6M | $2.7M | $177K | $1.1M | $45K | |
Free Cash Flow | -$322M | -$139.9M | -$105.5M | -$29.6M | -$31.7M |
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation.
In the current month, ALLK has received 0 Buy ratings 7 Hold ratings, and 0 Sell ratings. The ALLK average analyst price target in the past 3 months is $0.35.
According to analysts, the consensus estimate is that Allakos share price will rise to $0.35 per share over the next 12 months.
Analysts are divided on their view about Allakos share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Allakos is a Sell and believe this share price will drop from its current level to $0.30.
The price target for Allakos over the next 1-year time period is forecast to be $0.35 according to 7 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 7 analysts rate the stock a Hold.
According to Wall Street analysts, the consensus rating for Allakos is a Hold. 7 of 7 analysts rate the stock a Hold at this time.
You can purchase shares of Allakos via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Allakos shares.
Allakos was last trading at $0.25 per share. This represents the most recent stock quote for Allakos. Yesterday, Allakos closed at $0.26 per share.
In order to purchase Allakos stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Signup to receive the latest stock alerts
The AI race has heated up significantly but returns on…
Trimble (NASDAQ:TRMB) is a hardware and software tech company that…
It seems like right now is a good time to…
Market Cap: $3.6T
P/E Ratio: 39x
Market Cap: $2.8T
P/E Ratio: 32x
Market Cap: $2.6T
P/E Ratio: 36x
Willdan Group [WLDN] is down 3.66% over the past day.
Pro-Dex [PDEX] is up 10.33% over the past day.
Samsara [IOT] is down 3.68% over the past day.